Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

Exclusion Criteria

• •1. Clinically significant arrhythmia, defined as any arrhythmia requiring ongoing IV antiarrhythmic therapy.
• •2. Patients who are hemodynamically unstable, defined as mean arterial pressure ≤65 mmHg or heart rate ≤40 beats per minute or ≥125 beats per minute at time of screening
• •3. Hyperkalemia solely due to overdose on potassium supplements
• •4. Known bowel obstruction
• •5. Subjects currently being treated with or having taken potassium binders (e.g., patiromer, sodium or calcium polystyrene sulfonate or sodium zirconium cyclosilicate) in the 7 days prior to baseline
• •6. Subjects expected to receive dialysis during the first 6 hours of the study treatment period
• •7. Known hypersensitivity to patiromer or its ingredients
• •8. Participation in any other investigational device or drug study \<30 days prior to screening, or current treatment with other investigational agent(s)
• •9. Inability to consume the investigational product or, in the opinion of the Investigator unsuitable for study participation
• •10. Life expectancy of less than 6 months
• •11. Patients with automatically timed medication orders to control potassium in the ED
• •12. Patient is known to be pregnant or breastfeeding
• •13. An employee of investigational site or sponsors